Results 71 to 80 of about 1,466,333 (379)

Selective recruitment of γδ T cells by a bispecific antibody for the treatment of acute myeloid leukemia

Leukemia, 2021
Despite significant progress over the last few decades in the treatment of acute myeloid leukemia (AML), there still remains a major unmet medical need for this disease.
R. Ganesan, Vijaykumar Chennupati, B. Ramachandran, M. Hansen, Sanjaya Singh, I. Grewal   +5 more
semanticscholar   +1 more source

Unlocking the potential of anti-CD33 therapy in adult and childhood acute myeloid leukaemia [PDF]

, 2017
Acute Myeloid Leukaemia (AML) develops when there is a block in differentiation and uncontrolled proliferation of myeloid precursors, resulting in bone marrow failure.
Gibson, Brenda E.S., Harrison, Christine J., Keeshan, Karen, Laing, Alison A.   +3 more
core   +1 more source

Novel anti-4-1BB×PD-L1 bispecific antibody augments anti-tumor immunity through tumor-directed T-cell activation and checkpoint blockade

Journal for ImmunoTherapy of Cancer, 2021
Background Stimulation of 4-1BB with agonistic antibodies is a promising strategy for improving the therapeutic efficacy of immune checkpoint inhibitors (ICIs) or for overcoming resistance to ICIs.
Seongju Jeong, Eun Hwa Park, Hyung-Don Kim, Eunsil Sung, Hyunjoo Kim, Jaehyoung Jeon, Youngkwang Kim, Ui-jung Jung, Yong-gyu Son, Y. Hong, Hanbyul Lee, Shinai Lee, Y. Lim, J. Won, Minwoo Jeon, Shin Hwang, L. Fang, Wenqing Jiang, Zhengyi Wang, E. Shin, Su‐Hyung Park, Jaeho Jung   +21 more
semanticscholar   +1 more source

Chemical generation of bispecific antibodies [PDF]

Proceedings of the National Academy of Sciences, 2010
Bispecific antibodies (BsAbs) are regarded as promising therapeutic agents due to their ability to simultaneously bind two different antigens. Several bispecific modalities have been developed, but their utility is limited due to problems with stability and manufacturing complexity.
Jie Huang, Bryan Oates, Curt W. Bradshaw, Michael J. Shields, Bin Liu, Richard A. Lerner, Joselyn Del Rosario, Crystal Hagen, Dingguo Liu, Lingna Li, Ping Jin, Michelle Parish, Robert E. Murphy, Gary Woodnutt, Jing-Yu Lai, Joel Desharnais, Marla J. Matin, Zemeda W Ainekulu, Abhijit Bhat, Nancy Levin, Venkata Doppalapudi, Rodney W. Lappe   +21 more
openaire   +3 more sources

A Novel Bispecific Antibody Targeting PD-L1 and VEGF With Combined Anti-Tumor Activities

Frontiers in Immunology, 2021
Therapeutic monoclonal antibodies (mAbs) blocking immune checkpoints have been mainly used as monotherapy. Recently, combination therapy targeting multiple immune checkpoints has recently been explored to increase anti-cancer efficacy.
Xiaohui Cui, Huifeng Jia, H. Xin, Lei Zhang, Shi Chen, Simin Xia, Xia Li, Weiliang Xu, Xiaofang Chen, Yujie Feng, Xiaoyue Wei, Haijia Yu, Yanting Wang, Y. Zhan, Xiangyang Zhu, Xuemei Zhang   +15 more
semanticscholar   +1 more source

Development of a Bispecific Antibody Targeting CD30 and CD137 on Hodgkin and Reed-Sternberg Cells

Frontiers in Oncology, 2019
Hodgkin Lymphoma (HL) is a malignancy that frequently affects young adults. Although, there are effective treatments not every patient responds, necessitating the development of novel therapeutic approaches, especially for relapsed and refractory cases ...
Sakthi Rajendran, Sakthi Rajendran, Yating Li, Yating Li, Evelyn Ngoh, Hiu Yi Wong, Hiu Yi Wong, Man Si Cheng, Man Si Cheng, Cheng-I Wang, Herbert Schwarz, Herbert Schwarz   +11 more
doaj   +1 more source

Dual anti-idiotypic purification of a novel, native-format biparatopic anti-MET antibody with improved in vitro and in vivo efficacy [PDF]

, 2016
Bispecific antibodies are of great interest due to their ability to simultaneously bind and engage different antigens or epitopes. Nevertheless, it remains a challenge to assemble, produce and/or purify them.
Basilico, Cristina, Blanchetot, Christophe, de Haard, Hans, De Jonge, Natalie, El Khattabi, Mohamed, Godar, Marie, Hanssens, Valérie, Hultberg, Anna, Lambrecht, Bart, Michieli, Paolo, Morello, Virginia, Sadi, Ava, Saunders, Michael   +12 more
core   +2 more sources

Teclistamab is an active T cell-redirecting bispecific antibody against B-cell maturation antigen for multiple myeloma.

Blood Advances, 2020
B-cell maturation antigen (BCMA), a member of the tumor necrosis factor family of receptors, is predominantly expressed on the surface of terminally differentiated B cells.
K. Pillarisetti, G. Powers, L. Luistro, A. Babich, E. Baldwin, Yingzhe Li, Xiaochun Zhang, M. Mendonca, Nate Majewski, Rupesh K. Nanjunda, Diana Chin, K. Packman, Y. Elsayed, R. Attar, F. Gaudet   +14 more
semanticscholar   +1 more source

Circulating tumor cells: advancing personalized therapy in small cell lung cancer patients

Molecular Oncology, EarlyView.
Small cell lung cancer (SCLC) is an aggressive form of lung cancer that spreads rapidly to secondary sites such as the brain and liver. Cancer cells circulating in the blood, “circulating tumor cells” (CTCs), have demonstrated prognostic value in SCLC, and evaluating biomarkers on CTCs could guide treatment decisions such as for PARP inhibitors ...
Prajwol Shrestha, Steven Kao, Veronica K. Cheung, Wendy A. Cooper, Nico van Zandwijk, John E. J. Rasko, Dannel Yeo   +6 more
wiley   +1 more source

Phenotypic plasticity in a novel set of EGFR tyrosine kinase inhibitor‐adapted non‐small cell lung cancer cell lines

FEBS Open Bio, EarlyView.
Phenotypic plasticity in a newly established set of EGFR inhibitor‐adapted NSCLC cell lines during adaptation and in established cell lines. Here, we introduce novel sublines of the EGFR‐mutant non‐small cell lung cancer (NSCLC) cell lines HCC827 and HCC4006 adapted to the EGFR kinase inhibitors gefitinib (HCC827rGEFI2μm, HCC4006rGEFI1μm), erlotinib ...
Tharsagini V. Nanthaprakash, Campbell W. Gourlay, Ina Oehme, Michelle D. Garrett, Jindrich Cinatl Jr, Mark N. Wass, Martin Michaelis   +6 more
wiley   +1 more source